NKTR Nektar Therapeutics

-0.21  -1%
Previous Close 40.26
Open 40.58
Price To Book 3.87
Market Cap 6932063502
Shares 173,085,231
Volume 2,255,929
Short Ratio
Av. Daily Volume 1,958,979

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 updated data February 11, 2019 noted ORR to 48% (13/27) in patients with urothelial carcinoma.
NKTR-214 + OPDIVO (nivolumab) - PIVOT-2
Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers
Phase 1/2 commencement of dosing announced September 12, 2017. Initial data presented at ASCO 2018
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
PDUFA date May 29, 2019. Advisory Committee Meeting likely 1Q/2Q 2019.
Lower back pain
Phase 3 data released November 24, 2017. Endpoints not met.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)
Phase 1 data to be presented at ASCO-SITC Feb 28-Mar 2, 2019.
NKTR-262 and NKTR-214 - REVEAL
Solid tumors
Phase 1b initiation announced May 8, 2018.
Systemic lupus erythematosus (SLE)

Latest News

  1. Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets
  2. Is Nektar Therapeutics (NASDAQ:NKTR) A Financially Strong Company?
  3. Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed the Company According to Shareholder Lawsuit
  4. 3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys?
  5. Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients
  6. Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium
  7. Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth
  8. 8 Stocks That Can Lead in a 'Micro-Driven' Market
  9. 9 U.S. Stocks That Are Coming to Life Again
  10. The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares
  11. Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium
  12. Why Nektar Therapeutics Stock Gained 29% in January
  13. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  14. Mizuho's 9 Best Biotech Stocks to Buy for 2019
  15. 5 "Strong Buy" Stock Picks for 2019 (That Crashed in 2018)
  16. Is Bristol-Myers Squibb a Bargain Now?
  17. These beaten-down stocks are expected to roar back in 2019
  18. Here's Why Nektar Therapeutics Gave Back 45% in 2018